ReviewHepatic medicine : evidence and research2015
Interferon-free combination therapies for the treatment of hepatitis C: current insights.
Review in Hepatic medicine : evidence and research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and Safety of Ribavirin with Sofosbuvir Plus Ledipasvir in Patients with Genotype 1 Hepatitis C: A Meta-Analysis.Digestive diseases and sciences · 2016Pooled it
- Does Treatment of Hepatitis C Reduce Inhibitor Titers in Hemophilia A?Turkish journal of haematology : official journal of Turkish Society of Haematology · 2022Article
- Design and Synthesis of Novel Symmetric Fluorene-2,7-Diamine Derivatives as Potent Hepatitis C Virus Inhibitors.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Impact of sofosbuvir/ledipasvir versus sofosbuvir/daclatasvir regimens on the male sexual function of patients with chronic hepatitis C.Le infezioni in medicina · 2021Article
- Indole - a promising pharmacophore in recent antiviral drug discovery.RSC medicinal chemistry · 2020Review
- Sustained virological response in patients with HCV treated with daclatasvir plus sofosbuvir, with or without ribavirin: a large, field-practice study.Drugs in context · 2020Article
- Implementation of a pharmaceutical care program for patients with hepatitis C treated with new direct-action antivirals.International journal of clinical pharmacy · 2019Article
- Resolved HBV behavior during the treatment of chronic HCV infection with direct-acting antivirals.Gastroenterology and hepatology from bed to bench · 2019Article
- Late Relapse after a Sustained Virologic Response at 24 Weeks after Treatment with Daclatasvir and Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b Infection with Liver Cirrhosis.Internal medicine (Tokyo, Japan) · 2018Article
- Comorbidities and medications of patients with chronic hepatitis C under specialist care in the UK.Journal of medical virology · 2017Article
- Hepatitis B reactivation during or after direct acting antiviral therapy - implication for susceptible individuals.Expert opinion on drug safety · 2017Review
- Protease inhibitors for the treatment of hepatitis C virus infection.GMS infectious diseases · 2017Review
- Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver Disease.Clinical drug investigation · 2017Article
- Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint.Tropical medicine & international health : TM & IH · 2016Article
- Article
- Twelve-week ribavirin-free direct-acting antivirals for treatment-experienced Chinese with HCV genotype 1b infection including cirrhotic patients.Hepatology international · 2016Observational
- Pharmacologic Considerations in the Treatment of Hepatitis C Virus in Persons With HIV.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2016Review
- Incidence and risk factors of hepatitis C virus infection among human immunodeficiency virus (HIV) patients in a large HIV clinic in South Korea.The Korean journal of internal medicine · 2016Article
- Portal Hypertension Complications Are Frequently the First Presentation of NAFLD in Patients Undergoing Liver Transplantation Evaluation.Digestive diseases and sciences · 2016Article
- Challenging hepatitis C-infected liver transplant patients.Hepatic medicine : evidence and research · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The hepatitis C virus (HCV) treatment landscape has rapidly changed over the past 5 years. The development of direct-acting antiviral (DAA) agents that specifically target various steps in the HCV lifecycle has revolutionized therapeutic options for patients with HCV, with the development of highly effective and well-tolerated oral interferon-free regimens. There are many DAAs that are currently in development or have recently been approved, which target different nonstructural HCV proteins and host targets that are essential for HCV replication. This review will focus on the different classes of DAAs and the various combinations that are in advanced development for the treatment of chronic HCV infection and will focus on the different regimens in specific patient populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.